ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
23 avr. 2020 09h15 HE
|
BioSig Technologies, Inc.
Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in...
Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
21 avr. 2020 14h36 HE
|
BioSig Technologies, Inc.
Westport, CT, April 21, 2020 (GLOBE NEWSWIRE) -- Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm) – a...
BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials
21 avr. 2020 10h15 HE
|
BioSig Technologies, Inc.
Westport, CT, April 21, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that on April 16, 2020 its subsidiary ViralClear...
BioSig Issues April 2020 Shareholder Update Letter
17 avr. 2020 14h07 HE
|
BioSig Technologies, Inc.
Westport, CT, April 17, 2020 (GLOBE NEWSWIRE) -- Information on the progress of our subsidiary ViralClear Pharmaceuticals and Vicromax(tm) – a broad-spectrum orally administered anti-viral candidate...
Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax™
16 avr. 2020 09h45 HE
|
BioSig Technologies, Inc.
Westport, CT, April 16, 2020 (GLOBE NEWSWIRE) -- Broad Spectrum Antiviral Produced by ViralClear Pharmaceuticals, Inc., a subsidiary of BioSig Technologies, Inc.IND filing with FDA expected in...
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
09 avr. 2020 08h22 HE
|
BioSig Technologies, Inc.
Westport, CT, April 09, 2020 (GLOBE NEWSWIRE) -- Vicromax shown to decrease viral production of Covid -19 coronavirus by over 98%Article highlights recent work done in laboratory studies of Covid...
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
03 avr. 2020 13h10 HE
|
BioSig Technologies, Inc.
Westport, CT, April 03, 2020 (GLOBE NEWSWIRE) -- Introduction to ViralClear management and scientific teamStrategy for rapid FDA advancement of Vicromax(tm)Update on BioSig core business...
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
31 mars 2020 08h45 HE
|
BioSig Technologies, Inc.
Westport, CT, March 31, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
25 mars 2020 07h52 HE
|
BioSig Technologies, Inc.
Westport, CT, March 25, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board
10 mars 2020 08h05 HE
|
BioSig Technologies, Inc.
Westport, CT, March 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...